Skip to main content
Premium Trial:

Request an Annual Quote

Acacia Will Use $2.9M from Stock Sale to Fund Dx, Product Development at CombiMatrix

NEW YORK, June 30 (GenomeWeb News) - CombiMatrix parent Acacia Research plans to raise $2.9 million in a private placement of its Acacia Research-CombiMatrix common stock, the company said today.


The cash will go to Acacia's balance sheet, it will help fund CombiMatrix's entry into the molecular diagnostics market, and it will support the company's "long-term strategy" of developing new products for its CustomArray line, the company said in a statement.


Terms of the deal call for Acacia to sell 1,300,444 shares of it's the common stock at $2.25 per share to an undisclosed "select" group of institutional investors. The closing of the offering is expected to take place on July 5, subject to certain customary closing conditions.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.